Gilead Sciences Inc

NASDAQ: GILD
$89.88
+$0.74 (+0.8%)
Closing Price on January 10, 2025

GILD Articles

DryShips, Teva, Endo Pharma, and Gilead Sciences posted new 52-week lows Monday.
A new Jefferies research report makes the case that while market parameters are indeed expensive, there still are cheap stocks to buy that have a large enough market cap to provide some safety.
As we have approached Trump’s inauguration, the health care sector in general has rallied. Now it’s time to see what the bears have to say about this rally.
Needless to say, the past two years have been rough on biotech. The question for investors is which of the stocks hold the best potential in 2017.
The December 15 short interest data have been compared with the previous report, and short interest was down in most of the selected biotech stocks.
The November 30 short interest data have been compared with the previous report, and short interest was mixed in the selected biotech stocks.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. December 8, 2016: Here are four stocks trading with...
The November 15 short interest data have been compared with the previous report, and short interest increased in most of the selected biotech stocks.
Gilead Sciences has announced that the FDA has approved its once-a-day treatment for adults with chronic hepatitis B virus infection.
Now that the U.S. presidential election is over and Hillary Clinton is out of the picture, major biotech companies can breathe a little easier knowing that the pressure is off, if for just now at...
If you just looked at formal Buy and Sell ratings from Wall Street analysts, you might assume that everything is still fine and hopeful for Gilead Sciences.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Gilead Sciences Inc. (NASDAQ: GILD) released...
Although Gilead has been falling for about a year now, the valuation is looking more favorable — assuming Gilead is not a value trap. The earnings report will help shed some light on where the...
24/7 Wall St. has put together a preview of Pfizer, Starbucks and some of the major companies reporting their quarterly results this week.
The October 14 short interest data have been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.